Cabaletta Bio
CABA
142 hedge funds and large institutions have $380M invested in Cabaletta Bio in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 35 closing their positions.
117% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $685K
10% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 49
0.6% less ownership
Funds ownership: 105.83% → 105.22% (-0.6%)
11% less funds holding
Funds holding: 159 → 142 (-17)
46% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 35
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
56% less capital invested
Capital invested by funds: $871M → $380M (-$491M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$26M |
| 2 |
Alkeon Capital Management
New York
|
+$26M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$17.3M |
| 4 |
JP Morgan Chase
New York
|
+$11.4M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$21.3M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$19.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.8M |
| 4 |
PA
Perceptive Advisors
New York
|
-$13.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.4M |
CABA Hedge Fund Activity: Q2 2024 in Review
142 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q2 2024, worth a combined $380M — down 56% from $871M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CABA and 19 opened new positions — a net loss of 16 holders — while 49 trimmed existing stakes and 54 added.
The largest buyer was Jennison Associates, adding an estimated $26M. The largest seller was State Street, cutting an estimated $21.3M.
- 142 institutional investors held Cabaletta Bio (CABA) as of Q2 2024, down from 159 in Q1 2024.
- Funds reported $380M of Cabaletta Bio stock for Q2 2024, down 56% quarter-over-quarter.
- 19 funds opened new Cabaletta Bio positions in Q2 2024 and 35 closed out, a net change of -16 holders.
- The largest Cabaletta Bio buyer in Q2 2024 was Jennison Associates, an estimated $26M added.
- The largest Cabaletta Bio seller in Q2 2024 was State Street, an estimated $21.3M sold.
Based on aggregated 13F filings for Q2 2024.